STOCK TITAN
  1. Home
  2. News
  3. DNAA

Social Capital Suvretta Holdings Corp I - DNAA STOCK NEWS

IMPACT
SENTIMENT
AKLI : Nasdaq DNAA : Nasdaq
Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I
IMPACT
SENTIMENT
PRTC : Nasdaq DNAA : Nasdaq
PureTech Founded Entity Akili Announces Public Company Board of Director Nominees
IMPACT
SENTIMENT
DNAA : Nasdaq
Akili Announces Public Company Board of Director Nominees
IMPACT
SENTIMENT
DNAA : Nasdaq RBLX : NYSE
Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox
partnership
IMPACT
SENTIMENT
PRTC : Nasdaq DNAA : Nasdaq CPSR : NYSE
PureTech Announces Annual Results for Year Ended December 31, 2021
IMPACT
SENTIMENT
PRTC : Nasdaq DNAA : Nasdaq
PureTech Founded Entity Akili Announces American Journal of Psychiatry Publication of Data Demonstrating its Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults w/ Major Depressive Disorder When Combined w/ Antidepressant Medication
IMPACT
SENTIMENT
DNAA : Nasdaq
The American Journal of Psychiatry Publishes Data Demonstrating Akili Interactive’s Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults with Major Depressive Disorder When Combined with Antidepressant Medication
IMPACT
SENTIMENT
DNAA : Nasdaq
Akili to Present at Chardan’s Prescription Digital Therapeutics Half-Day Summit
conferences
IMPACT
SENTIMENT
PRTC : Nasdaq DNAA : Nasdaq
PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer
management
IMPACT
SENTIMENT
DNAA : Nasdaq
Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer
Stock DNAA logo
Social Capital Suvretta Holdings Corp I

Nasdaq:DNAA

DNAA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

DNAA Stock Data

About DNAA

Social Capital Suvretta Holdings Corp. I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on businesses operating in the biotechnology industry and within the neurology subsector.